Introduction {#Sec1}
============

Cognitive impairments are a central feature of many neuropsychiatric conditions, including stimulant dependence, attention deficit hyperactivity disorder, and schizophrenia; they are also a feature of normal aging, prompting recent therapeutic focus on cognitive enhancement. Disease- and age-related impairments are often particularly pronounced on prefrontal cortex-dependent tests involving working memory. Performance on such tests is amenable to dopaminergic modulation (Mehta et al. [@CR44]). However, not everybody benefits equally from boosting dopamine transmission, as the effects of dopaminergic agents depend on the nature of the task and baseline dopamine neurotransmission in the brain (Arnsten [@CR3]). Being able to predict pharmacological effects on tests of cognitive function could offer a promising opportunity for neuropsychiatry, as cognitive performance is strongly related to psychosocial functioning in patients (Green [@CR31]) and facilitates their retention in treatment (Aharonovich et al. [@CR1]).

Besides its effects on cognitive function, dopamine is also an important modulator of motivated behavior for natural and drug rewards (Berridge and Robinson [@CR8]; Everitt and Robbins [@CR24]; Kelley and Berridge [@CR35]; Schultz [@CR55]). Dopamine receptors are implicated in the reinforcing effects of stimulant drugs such as cocaine or amphetamines (Koob [@CR38]; Wise and Bozarth [@CR70]). Despite the important role dopamine plays in addictive behavior, it has been difficult to delineate the exact roles of the various dopamine receptor types in drug addiction (Foll et al. [@CR26]). Research in experimental monkeys has shown that chronic abuse of stimulant drugs reduces dopamine D~2~ receptor levels throughout the striatum (Nader et al. [@CR46]). Indeed, reduced D~2~ and D~3~ receptor densities, as measured with positron emission tomography (PET), have been documented in abstinent stimulant-dependent individuals (SDIs). Importantly, this reduction in D~2/3~ receptors in the midbrain appears to be associated with hypo-metabolism in prefrontal cortex (PFC; Volkow et al. [@CR67]; Volkow et al. [@CR68]), which is likely to contribute to cognitive dysfunction and the maladaptive behavior patterns seen in individuals with stimulant dependence (Goldstein and Volkow [@CR28]). One possible pharmacological strategy would be to increase dopamine transmission in the striatum and to reduce symptoms of stimulant withdrawal and craving. However, the therapeutic efficacy of dopamine agonists for this indication has been inconsistent (Grabowski et al. [@CR30]; Shearer et al. [@CR57]; Soares et al. [@CR60]).

Dopaminergic neurotransmission in the PFC is itself influenced by the activity of the enzyme catechol-*O*-methyltransferase (COMT), which is implicated in dopamine catabolism (Axelrod and Tomchick [@CR4]) and PFC-dependent cognition (Tunbridge et al. [@CR65]). One association study has suggested that an interaction between COMT and dopamine D~4~ receptor polymorphisms may influence the risk for the development of stimulant abuse (Li et al. [@CR39]). The D~4~ receptor, in contrast to D~2~ and D~3~ receptors, is mainly located in brain areas innervated by mesocortical dopamine pathways, such as the PFC (Meador-Woodruff et al. [@CR43]; Tarazi and Baldessarini [@CR64]). Since dopamine provides an important modulatory influence on cognitive functions subserved by prefrontal networks, such as working memory (Robbins and Arnsten [@CR51]), markers of dopamine neurotransmission may be able to identify individuals who might experience the greatest cognitive benefits from dopaminergic treatment. Corroborating this idea, it was recently demonstrated that D~2/3~ receptor availability in the striatum, assessed with PET, was associated with cognitive performance following methylphenidate administration (Clatworthy et al. [@CR16]). These data suggest that central dopamine receptor expression may be predictive of response to dopaminergic drugs, but clearly, the cost, invasiveness, and radiation risk of PET effectively preclude this technique as a routine clinical tool for assessment of dopamine receptor status.

However, markers of dopamine receptor gene expression in the D2-receptor family (D~3~ and D~4~ receptor subtypes) are not only detectable in the brain but also expressed in peripheral blood, where dopamine plays a pivotal role in mediating communication between the nervous and immune systems (Basu and Dasgupta [@CR6]; Eskandari and Sternberg [@CR23]). Based on observations showing altered dopamine receptor expression in peripheral blood cells in patients with known abnormalities in the central dopamine transmission (Ilani et al. [@CR34]; Nagai et al. [@CR47]), it has been suggested that dopamine receptor mRNA expression in circulating blood might reflect the dopamine receptor level in the brain (Ilani et al. [@CR34]) and might serve as a useful surrogate marker for more direct measurements of central receptor status in the brain (Gladkevich et al. [@CR27]).

In the present study, we investigated the effects on cognitive performance of a single dose of the selective dopamine D~2/3~ agonist pramipexole (0.5 mg) in 36 volunteers, half with a diagnosis of cocaine or amphetamine dependence and half with no history of substance abuse/dependence. Specifically, we hypothesized that peripheral dopamine markers (i.e., DRD3, DRD4, and COMT mRNA levels in whole blood) would be predictive of individual differences in performance on PFC-dependent cognitive tests following pramipexole treatment. In individuals with stimulant dependence, we also predicted that peripheral dopamine markers might be associated with the severity of addictive symptoms.

Methods and materials {#Sec2}
=====================

Participants {#Sec3}
------------

Thirty-six volunteers participated in the study: 18 individuals with a chronic history of stimulant drug abuse (SDIs), meeting the *Diagnostic and Statistical Manual of Mental Disorders-Text Revision* (*DSM-IV-TR*; American Psychiatric Association [@CR2]) criteria for dependence on either cocaine/crack-cocaine (*n* = 10) or amphetamines (*n* = 8), and 18 matched healthy controls without a history of substance abuse/dependence. Diagnosis was ascertained using the Structured Clinical Interview for *DSM-IV* (First et al. [@CR25]). Sixteen SDIs also met *DSM-IV* criteria for nicotine dependence, two for cannabis dependence, and five for alcohol abuse. Half the SDIs smoked cannabis regularly (50%) and consumed other drugs sporadically (ecstasy 33%, hallucinogens 22%, benzodiazepines 6%, and opiates 6%). The non-drug-using volunteers were recruited from the GlaxoSmithKline Clinical Unit Cambridge panel. Eleven percent smoked cannabis sporadically, 5% were occasional tobacco smokers, and 28% had previously smoked tobacco. Urine samples provided by SDIs tested positive for stimulants on each testing visit; all healthy volunteer urine samples were negative. At a baseline assessment, participants completed the National Adult Reading Test (NART, Nelson [@CR48]) to provide an estimate of verbal IQ, the Beck Depression Inventory (BDI-II, Beck et al. [@CR7]) to record dysphoric mood, and the Barratt Impulsiveness Scale (BIS-11, Patton et al. [@CR50]) to assess trait-impulsivity. The protocol was approved by the Cambridge Research Ethics Committee (REC06/Q0108/130; principal investigator: TWR). All volunteers provided written informed consent prior to study enrolment.

Experimental procedures {#Sec4}
-----------------------

We used a randomized, double-blind, placebo-controlled, cross-over design. On each session, a single dose of placebo or pramipexole was administered in counterbalanced order. Pramipexole was chosen on the basis of its selective profile for D~2/3~ receptors, particularly in mesolimbic brain areas (Catnacho-Ochoa et al. [@CR13]; Suzuki et al. [@CR63]). The study also included a dopamine D~2/3~ antagonist intervention using amisulpride, (data reported elsewhere: Ersche et al. [@CR22]).

We administered pramipexole at a dose of 1.5 mg to the first six volunteers (three SDIs and three controls). While the SDIs tolerated this dose, this was not the case for the controls, who were unable to perform any cognitive tests due to nausea, vomiting, sweating, and tiredness. These controls were subsequently administered 0.5 mg pramipexole on a separate testing session, which was tolerated well. Thereafter, all remaining participants received 0.5 mg pramipexole. In total, we included data from 18 controls and 18 SDIs (three of whom were administered the 1.5-mg dose).

On each visit, participants took domperidone tablets (30 mg) as a pre-treatment to prevent emetic side effects. Domperidone is a peripheral D~2~ antagonist that does not cross the blood--brain barrier (Champion [@CR14]). At 2.5 and 4 h after dosing, blood samples were drawn for assessment of drug plasma concentrations. The time elapsed between administration of dopaminergic treatment and SDIs' last use of illicit stimulants was similar between the two treatment conditions \[placebo, 8.5 h (SD ± 5.6) and pramipexole 8.6 h (SD ± 5.7); *F* \< 1\]. Approximately 180 min after dosing, participants performed four tests from the computerized Cambridge Neuropsychological Test Automated Battery (CANTAB; [www.camcog.com](http://www.camcog.com)) and the digit-span subtest of the Wechsler Adult Intelligence Scale (WAIS, Wechsler [@CR69]).

The testing sessions were separated by at least 1 week to prevent carry-over effects, verified by the analysis of prolactin levels in blood drawn immediately before dosing on each testing session.

Cognitive measures {#Sec5}
------------------

The Spatial Working Memory (SWM, Robbins et al. [@CR52]) test is a self-ordered search task in which participants have to search through a spatial array of colored boxes for tokens, without returning to a box which had already contained a token. The number of errors was measured, including returning to a box in which a token was already found and returning to a box that was already found to be empty.

Rapid Visual Information Processing (RVIP, Sahakian et al. [@CR54]) is a test of sustained attention, where a series of single digits (ranging from 2 to 9) is presented one at a time (100 digits/min) in a random order. Following a training sequence, participants detect three-digit target sequences by pressing the response pad. Sustained attention ability was measured by the metric A′, a signal detection measure of sensitivity to targets independent of the general overall tendency to respond, calculated using both the probability of hits and the probability of false alarms.

Paired Associates Learning (PAL, Sahakian et al. [@CR54]) assesses episodic memory and learning of geometric patterns and spatial locations. Participants are shown six boxes, and in the last trial, eight boxes, which briefly disclose an abstract pattern. Once all the patterns have been briefly displayed, participants are shown the patterns one at a time and asked to select the location where they were previously displayed. The total number of errors was recorded.

The Information Sampling Task (IST, Clark et al. [@CR15]) measures the tendency to gather information prior to making a simple probabilistic decision about which color of a hidden two-colored five-by-five matrix is in the majority. Prior to making the decision, participants have the opportunity to gather as much information about the color of the matrix as they feel they need for making a correct choice. The number of boxes opened, i.e., the number of elements in the matrix which are known to the participant at the time of decision-making, was recorded.

In the digit-span test (Wechsler [@CR69]), participants have to listen to an increasingly long list of digits presented for immediate recall in either the exact order presented (forward span) or in the reverse order (backward span). The score reflects the maximum number of digits participants can successfully retain in working memory. Since the backward span has been considered to be more demanding on working memory resources than the forward span (Silver et al. [@CR58]), we focused on the backward condition.

mRNA extraction and analysis {#Sec6}
----------------------------

On the second testing visit, prior to drug administration, a peripheral blood sample (2.5 ml) was drawn into PAXgene tubes (PreAnalytiX GmbH), and total mRNA was isolated using the PAXgene Blood RNA System (PreAnalytiX GmbH). The use of whole blood collected into PAXgene tubes was chosen to maximize the stability of the dopamine receptor mRNA and to avoid potential artifactual changes from isolating individual peripheral cell types. RNA purity and concentration was determined by UV spectrophotometry. Total RNA (400 ng in 100 μl) was reverse-transcribed into first-strand cDNA using Multiscribe^TM^ Reverse Transcriptase (Applied Biosystems) and Oligod(T)~16~ primers. Amplification of the DRD3, DRD4, and COMT target genes was carried out using a 7900 ABI Prism Sequence Detection System (Applied Biosystems) using 20 ng of cDNA in 25 μl of reaction mixture by gene-specific primers using the following Assay-on-Demand Gene Expression Assays (Applied Biosystems); DRD3 (Hs00364455_M1), DRD4 (Hs00609526_M1), and COMT (Hs00241349_M1), β**-**actin (4333762F), GAPDH (4333764F), and cyclophilin A (4333763F). Amplification efficiency was guaranteed for all the aforementioned TaqMan Gene Expression assays by Applied Biosystems ([www.appliedbiosystems](http://www.appliedbiosystems)), and therefore, we did not further investigate gene expression relative to a standard curve, which might have provided us a more precise estimate of amplification efficacy. The PCR cycling parameters were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C for 15 s, and 60°C for 1 min. Relative DRD3, DRD4, and COMT mRNA levels were calculated using the threshold cycle for target amplification, Ct (target gene) − average Ct value (GAPDH, β-actin and cyclophiln A) to generate ∆Ct values. The average of the three reference genes was used for normalization since the resulting values should be less noisy than using any individual reference gene. However, correlations between the single housekeeper genes suggest that our key analyses would have been largely the same irrespective of which control gene was used for analysis, in particular for DRD3 and DRD4 (see [Supplemental Material](#AppESM1){ref-type="sec"}). Correlations of the ∆Ct values with those calculated with each of the individual reference genes were generally very high. The 2^-ΔΔCt^ method (Livak and Schmittgen [@CR40]) is a convenient way to analyze the relative changes in gene expression from real-time quantitative PCR experiments and was calculated for use in the analyses.

Dopamine receptor mRNA expression was not detectable in five samples (two SDIs, three controls); in one control volunteer, the DRD3 level was deviated more than eight standard deviations from the sample mean, and this sample was therefore excluded from the analysis. We initially wanted to extract all dopamine receptors of the D2 family from the blood, but mRNA of the DRD2 was not identified in our blood samples, which is consistent with previous reports showing that DRD2 expression in the blood is lower compared with the expression of DRD3 or DRD4 (Kirillova et al. [@CR37]).

Statistical analysis {#Sec7}
--------------------

Data were analyzed using the Statistical Package for the Social Sciences 13 (SPSS Inc.). In preparation for parametric analyses, digit-span and PAL data were square-root transformed to reduce skew (Howell [@CR33]), but untransformed values are displayed in the figures and tables. First, we fitted repeated-measures analysis of co-variance models to examine group differences in cognitive performance, the main effect of pramipexole administration compared with placebo, and the interaction between group and pramipexole treatment. Mean BDI scores and years of education were included as covariates.

We then focused on the associations between levels of each of the three mRNA transcripts measured (DRD3, DRD4, and COMT) and each of the five cognitive measures. To summarize the influence of pramipexole administration on cognitive performance, we calculated change scores for each individual on each test by subtracting the cognitive test scores following pramipexole from the scores following placebo. We then examined the effects of dopamine markers on change scores, as well as group-by-dopamine marker interactions; these analyses also included the effect of group. Where significant effects or interactions of dopamine markers were identified, we then calculated the Pearson's correlation co-efficient *r* for descriptive purposes.

Finally, we explored effects of drug treatment on symptom severity and possible associations between dopamine markers and treatment-related changes in symptom severity in SDIs. We calculated symptom change scores as the change in craving severity rating following pramipexole relative to placebo, 4 h following administration, corrected for baseline craving level. Symptom change scores were correlated with dopamine markers. We also estimated correlations between dopamine marker expression levels and baseline measures of symptom severity in the SDI group.

Correction for multiple comparisons was performed by dividing the initial *P* threshold (0.05) by 10, resulting in a threshold of *P* \< 0.005. However, since this was an exploratory analysis, results reaching the *P* \< 0.05 threshold are also reported, though not commented on in the discussion.

Results {#Sec8}
=======

Demographic and clinical variables {#Sec9}
----------------------------------

As shown in Table [1](#Tab1){ref-type="table"}, the groups were well-matched on age, verbal IQ, gender, and ethnicity, but SDIs had spent less time in full-time education, and as expected from the clinical literature (Booth et al. [@CR10]), SDIs also scored higher on the BDI-II than controls (Buckley et al. [@CR11]). Consequently, both variables were included as covariates in the first set of analyses, though not in the analyses of dopamine markers. Table 1Demographic and baseline measures for the groups of stimulant-dependent individuals (*n* = 18) and non-drug-taking comparison volunteers (*n* = 18)GroupHealthy controlStimulant-dependent*F*df*P* valuesAge (years)32.7 (±6.9)34.3 (±7.2)0.471, 340.498Gender ratio (male/female)15:315:3Fisher′s exact1.000Ethnic ratio (Caucasian/Afro-Caribbean)17:116:2Fisher′s exact1.000Verbal intelligence quotient (NART)108.4 (±6.0)109.0 (±8.1)0.551, 340.816Years of education12.4 (±1.8)11.2 (±1.0)6.851, 340.013Depressive mood (BDI-II total score)1.1 (±2.4)9.3 (±11.1)9.501, 340.004Impulsivity (BIS-11 total score)62.0 (±7.2)82.0 (±9.5)50.41, 34\<0.001Duration of stimulant abuse (years)--11.7 (±7,4)------Compulsivity of stimulant abuse (OCDUS score)--26.5 (±7.9)------Frequency of stimulant use (times per week)--5.4 (±2.0)------*NART* National Adult Reading Test, *BIS-11* Barratt Impulsiveness Scale, *BDI-II* Beck Depression Inventory, *OCDUS* Obsessive-Compulsive Drug Use Scale

Plasma pramipexole, prolactin, and mRNA levels {#Sec10}
----------------------------------------------

There was no significant difference in plasma levels of pramipexole between the two groups (*t*~18.6~ = 1.78, *P* \> 0.05), and pramipexole plasma levels did not correlate with mean cognitive performance following pramipexole treatment. Prolactin levels decreased following administration of pramipexole in both groups. At baseline (i.e., following the pre-treatment with domperidone and prior to dosing), there was no difference in prolactin levels between the groups (*F*~1,34~ = 0.01, *P* = 0.922) or between sessions (*F*~1,34~ = 0.04, *P* = 0.834). The groups did not differ in terms of peripheral DRD3 (*t*~28~ = 0.23, *P* \> 0.05), DRD4 (*t*~29~ = 0.08, *P* \> 0.05), or COMT (*t*~29~ = 0.49, *P* \> 0.05) mRNA levels. Peripheral dopamine markers were unrelated to demographic or personality variables, including years of education, impulsivity, and depressive mood. Furthermore, we did not identify any associations between mRNA expression and baseline performance that survived correction for multiple comparisons.

Effects of pramipexole and group on cognitive performance {#Sec11}
---------------------------------------------------------

Cognitive data are shown in Table [1](#Tab1){ref-type="table"}. SDIs performed significantly less accurately than controls on the SWM (*F*~1,32~ = 10.14 *P* = 0.003), digit-span (*F*~1,31~ = 5.00, *P* = 0.033), RVIP (*F*~1,32~ = 15.76, *P* \< 0.001), and PAL (F~1,32~ = 12.04, *P* = 0.002) tests and were marginally more impulsive on the IST (*F*~1,32~ = 3.71, *P* = 0.063), replicating our previous findings (Clark et al. [@CR15]; Ersche et al. [@CR21]). No main effect of pramipexole was identified on any of the measures. The only significant drug-by-group interaction was observed on the IST test (*F*~1,31~ = 6.67, *P* = 0.015). This interaction was driven by effects in the control participants, who performed less impulsively following pramipexole compared with placebo (*t*~17~ = −2.29, *P* = 0.035), while performance in the SDI group was unaffected by pramipexole (*t*~16~ = 0.53, *P* = 0.604). Stimulant craving increased significantly in SDIs over the course of the testing sessions (*F*~1,17~ = 12.2, *P* = 0.003), but the main effect of drug treatment (*F*~1,17~ = 1.33, *P* \> 0.1) and drug-by-time interaction (*F*~1,17~ = 0.15, *P* \> 0.5) were non-significant (see also Table [2](#Tab2){ref-type="table"}). Table 2Performance data (mean and standard deviation, SD) on placebo and pramipexole in controls (*n* = 18) and stimulant-dependent individuals (*n* = 18)GroupHealthy controlStimulant-dependentMeanSDMeanSD*F* (drug)*P* (drug)*F* (group)*P* (group)*F* (drug × group)*P* (drug × group)SWM-placebo17.6721.4031.9416.210.500.48410.140.0030.060.811SWM- pramipexole15.5613.0537.0617.33DS-placebo7.722.525.611.790.890.3535.000.0331.070.308DS-pramipexole8.062.755.672.47RVIP-placebo0.960.030.910.042.660.11311.570.0020.180.672RVIP-pramipexole0.950.030.900.05PAL-placebo4.944.1711.5610.403.310.07812.040.0020.470.499PAL-pramipexole6.948.2319.4415.52IST-placebo10.583.289.274.500.350.5603.710.0636.670.015IST-pramipexole11.793.218.624.48Task (dependent variable): SWM (total errors), *DS* digit-span (number), RVIP (A'), PAL (total errors), IST (number of boxes opened)

Associations between peripheral dopamine markers and pramipexole effects on cognitive test performance {#Sec12}
------------------------------------------------------------------------------------------------------

Results of all regression analyses relating dopamine biomarkers to pramipexole-induced changes in cognition are presented in Table [3](#Tab3){ref-type="table"}. Table 3Pramipexole-induced performance change in controls (*n* = 15) and stimulant-dependent individuals (*n* = 16)MarkerMarker × groupSWMDRD3F1, 26 = 9.86*P* = 0.004F1, 26 = 0.71*P* = 0.406DRD4F1, 27 = 0.06*P* = 0.802F1, 27 = 1.03*P* = 0.320COMTF1, 27 = 4.21*P* = 0.050F1, 27 = 0.20*P* = 0.658Digit-spanDRD3F1, 25 = 0.45*P* = 0.510F1, 25 = 4.32*P* = 0.048DRD4F1, 26 = 0.001*P* = 0.996F1, 26 = 11.12*P* = 0.003COMTF1, 26 = 2.43*P* = 0.131F1, 26 = 6.19*P* = 0.020RVIPDRD3F1, 26 = 4.24*P* = 0.050F1, 26 = 1.79*P* = 0.192DRD4F1, 27 = 0.67*P* = 0.419F1, 27 = 0.39*P* = 0.539COMTF1, 27 = 1.03*P* = 0.319F1, 27 = 0.02*P* = 0.880PALDRD3F1, 26 = 0.07*P* = 0.788F1, 26 = 0.001*P* = 0.991DRD4F1, 27 = 2.55*P* = 0.122F1, 27 = 0.01*P* = 0.910COMTF1, 27 = 1.76*P* = 0.196F1, 27 = 1.98*P* = 0.171ISTDRD3F1, 25 = 0.02*P* = 0.901F1, 25 = 0.18*P* = 0.672DRD4F1, 26 = 0.20*P* = 0.657F1, 26 = 0.02*P* = 0.884COMTF1, 26 = 0.96*P* = 0.337F1, 26 = 0.21*P* = 0.652

**DRD3** We identified a significant main effect of DRD3 mRNA levels on the pramipexole-induced change in SWM performance (*F*~1,26~ = 9.86, *P* \< 0.005). The group-by-DRD3 interaction was non-significant. Figure [1a](#Fig1){ref-type="fig"} illustrates this result: individuals with lower peripheral DRD3 mRNA levels exhibited improved accuracy on SWM performance following pramipexole administration. For the digit-span test, the main effect of DRD3 was non-significant, and the group-by-DRD3 interaction did not survive correction for multiple comparisons (*F*~1,25~ = 4.32, *P* = 0.048), as shown in Fig. [S1](#MOESM2){ref-type=""}a. For the RVIP test, the main effect of DRD3 did not survive correction for multiple comparisons (*F*~1,26~ = 4.24, *P* = 0.05), and the group-by-DRD3 interaction was non-significant (see Fig. [S1](#MOESM2){ref-type=""}b). On PAL and IST, no main effects of DRD3 or interactions were identified at a threshold of *P* \< 0.05. Fig. 1Relationships between peripheral biomarkers and cognitive/clinical measures. **a** Associations between peripheral DRD3 mRNA levels in blood cells and pramipexole-induced changes in accuracy in working memory; **b** Association between peripheral COMT mRNA levels in blood cells and severity of stimulant dependence, as reflected by the number of *DSM-IV* criteria satisfied for the diagnosis of dependence on stimulant drugs. Levels of mRNA were not detectable in five blood samples (two stimulant users, three controls)

**DRD4** For digit-span, although the main effect of DRD4 was non-significant, there was a significant group-by-DRD4 interaction (*F*~1,26~ = 11.12, *P* = 0.003) shown in Fig. [S2](#MOESM3){ref-type=""}a. Change in digit-span performance was negatively correlated with DRD4 in SDIs (*r* = −0.57, *P* = 0.017) and positively correlated in healthy volunteers (*r* = 0.52, *P* = 0.057). On the other cognitive tests, no main effects of DRD4 or interactions were detected at a threshold of *P* \< 0.05.

**COMT** For SWM, the main effect of COMT (*F*~1,27~ = 4.21, *P* = 0.050) did not survive correction for multiple comparisons, and the group-by-COMT interaction was non-significant (see Fig. [S2](#MOESM3){ref-type=""}c). For digit-span, the main effect of COMT was non-significant and the group-by-COMT interaction, as shown in Fig. [S2](#MOESM3){ref-type=""}b, but did not survive correction for multiple comparisons (*F*~1,26~ = 6.19, *P* = 0.020). No main effects of COMT or interactions were identified on RVIP and IST at a threshold of *P* \< 0.05.

Associations between peripheral dopamine markers, pramipexole effects on symptom severity, and baseline symptom severity {#Sec13}
------------------------------------------------------------------------------------------------------------------------

The correlation between DRD4 mRNA levels and pramipexole-induced changes in craving in the SDI group (*r* = 0.63, *P* = 0.009) did not survive correction for multiple comparisons, and no correlations with DRD3 or COMT were identified at a threshold of *P* \< 0.05.

With regard to baseline clinical variability in the SDI group, dopamine markers were unrelated to the duration, frequency, or compulsivity of stimulant abuse. However, peripheral levels of COMT mRNA were significantly correlated with the severity of stimulant dependence, as reflected by the number of criteria met according the *DSM-IV* (*r* = 0.78, *P* \< 0.001); see Fig. [1b](#Fig1){ref-type="fig"}.

Discussion {#Sec14}
==========

The results of our study provide direct experimental evidence in support of the potential utility of peripheral dopamine biomarkers to predict treatment response to dopamine agonist drugs and to provide objective correlates of variability in clinical severity of addiction to dopamine-releasing drugs.

Peripheral dopamine markers to predict drug response {#Sec15}
----------------------------------------------------

We found that peripheral D~3~ mRNA levels predict changes in working memory performance following a single dose of pramipexole. Although stimulant dependence has been associated with cognitive impairments (Ersche and Sahakian [@CR20]; Rogers and Robbins [@CR53]), the prediction of the pramipexole-induced performance change was independent of baseline performance or drug-taking history. Our findings are, however, in keeping with an inverted U-shaped function relating basal dopamine function with performance, i.e., those individuals with relatively low DRD3 mRNA expression should improve, while participants with relatively high peripheral expression levels should perform worse following dopamine agonist treatment. Our findings are also consistent with recent PET studies in which dopamine D~2/3~ receptor binding in the ventral striatum predicted methylphenidate-induced change in working memory performance in healthy volunteers (Clatworthy et al. [@CR16]) and dopamine synthesis capacity predicted the cognitive response to the dopamine agonist bromocriptine (Cools et al. [@CR18]). Given that the procedure for obtaining peripheral dopamine markers is minimally invasive and orders of magnitude less expensive than a PET scan, peripheral biomarkers could be attractive for future use in clinical practice.

The notion of predicting inter-individual variation in the effects of dopaminergic agents on cognition and behavior is not completely novel, although previous attempts have depended on the use of behavioral measures rather than peripheral biomarkers. Thus, trait-impulsivity (Cools et al. [@CR17]) or baseline working memory performance (Kimberg et al. [@CR36]) has previously been suggested to serve as indicators for cognitive change following dopamine agonist administration. However, the utility of these personality or performance indicators in psychiatric patients is questionable given that impulsivity is a key feature of several psychiatric disorders (Moeller et al. [@CR45]) and cognitive impairment is common in psychiatric conditions (Harrison and Owen [@CR32]). By contrast, the prediction of cognitive change by peripheral DRD3 mRNA expression was independent of self-reported impulsivity, mood, baseline cognitive performance, or psychiatric status. This implies that the use of dopamine mRNA level in circulating blood might be particularly suitable for mental health patients.

Our findings do not support the view that abnormalities of peripheral dopamine markers are related to the diagnosis of stimulant dependence per se (Czermak et al. [@CR19]), but suggest that these markers could be used to predict individual variability addiction severity. We found that the higher the levels of peripheral COMT mRNA in the blood, the more severely dependent the SDIs were. It has been suggested that the genetic polymorphism that regulates COMT activity in the brain may also regulate the levels of COMT activity in lymphocytes (Sladek-Chelgren and Weinshilboum [@CR59]). Higher COMT activity has repeatedly been suggested to be associated with increased vulnerability to the development of drug abuse (Beuten et al. [@CR9]; Li et al. [@CR39]; Vandenbergh et al. [@CR66]), consistent with our data. However, the relationship between COMT polymorphism and cocaine dependence has been inconsistent (Lohoff et al. [@CR41]). For other peripheral dopamine markers such as the DRD3 receptor a similar relationship with symptom severity has been identified in Parkinson's disease, i.e., a decrease in DRD3 mRNA levels was associated with the degree of clinical severity in these patients (Nagai et al. [@CR47]). Longitudinal studies would be needed to investigate the stability of these measures over time, given that the severity of substance dependence may change following therapeutic interventions.

Does expression of peripheral dopamine markers reflect levels in the brain? {#Sec16}
---------------------------------------------------------------------------

The mechanisms underlying the expression of dopamine receptor mRNA in the brain and in the periphery are not fully understood. It has been suggested that mRNA levels detectable peripherally in the blood reflect levels of expression in the brain (Caronti et al. [@CR12]; Ilani et al. [@CR34]; Pacheco-Lopez et al. [@CR49]), but evidence for this direct relationship is still lacking. While there are clear similarities in gene expression profiles in whole blood and brain tissue, variation in expression between tissue types also exists (Sullivan et al. [@CR62]). Between-subjects variation in gene expression may be driven by genetic polymorphisms, some of which regulate mRNA transcription, but this regulation might also vary across different tissues. Post-mortem analyses of stimulant users who died of a cocaine overdose showed a significant increase in both D~3~ receptors (Staley and Mash [@CR61]) and DRD3 mRNA levels (Segal et al. [@CR56]) in the nucleus accumbens compared with age-matched, drug-free control brains. Unfortunately, dopamine markers in peripheral blood in these samples were not analyzed, limiting direct comparison with the present study. The current uncertainties suggest that speculations about the comparability of gene expression peripherally and centrally must remain tentative.

PET studies in SDIs who had been drug abstinent for at least two weeks also showed a significant reduction in D~2/3~ receptor density in the striatum compared with non-drug-taking controls (Martinez et al. [@CR42]; Volkow et al. [@CR67]). Accordingly, a separate study in a different sample showed that peripheral dopamine receptor mRNA expression in lymphocytes was reduced in abstinent drug users (Czermak et al. [@CR19]). Our SDIs had been actively using stimulant drugs for an average of 11.7 years (SD ± 7.4) and did not differ from controls in terms of peripheral dopamine markers. One may speculate whether active drug use increases dopamine receptor mRNA, masking a pre-morbid down-regulation similarly to what reported for D~4~ and D~5~ mRNA expression in opiate-dependent individuals on methadone maintenance therapy (Goodarzi et al. [@CR29]). Support for this view comes from de novo patients with Parkinson's disease, whose dopamine receptor expression in lymphocytes normalized following three months treatment with [l]{.smallcaps}-DOPA or a dopamine agonist (Barbanti et al. [@CR5]).

Methodological issues and limitations {#Sec17}
-------------------------------------

Our findings may differ from biomarker results reported by other groups (Czermak et al. [@CR19]; Goodarzi et al. [@CR29]) as we extracted mRNA markers from whole blood not only from lymphocytes. We used whole blood to maximize the stability of the dopamine receptor mRNA and to avoid potential artifactual changes from isolating individual peripheral cell types. We cannot rule out that the pre-treatment with domperidone for the prevention of emetic side effects may have affected the levels of mRNA expression in the blood. This seems unlikely, however, because all our participants took the same dose of domperidone prior to drug treatment administration, and prolactin levels, assessed immediately before dosing of each drug treatment session, did not differ between the groups or between the treatment sessions.

Conclusions {#Sec18}
-----------

Our findings that peripheral D~3~ receptor mRNA levels predicted individual variability in working memory following dopamine agonist treatment suggest that such metrics might be usefully employed in clinical practice. The ability of peripheral biomarkers to predict response to dopamine agonist administration could have important implications for personalizing the treatment for psychiatric patients, allowing clinicians to predict which patients will receive greatest benefit from dopaminergic medications. It would be of great interest to examine the relationship between peripheral mRNA levels relating to neurotransmitter function and response to treatment in other neuropsychiatric disorders. Our data also speak to the ongoing debate about the potential utility of cognitive enhancing drugs to optimize performance in the context of normal cognitive variability over the lifecycle.
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